The goal of anti-TNF-α medication is to counteract the actions of TNF-α.In the clinical management of IBD, a range of anti-TNF-α medications, such as infliximab, adalimumaab, golimumab, certolizumab, etanercept, and onercept have been used or are currently being used [6].Computer-assisted drug design (CADD) has emerged as a viable technique for identifying promising leads and expediting the development of new medications to treat a wide range of ailments [7,8]. Here, TNF is linked to inflammatory bowel disease.